Capricor Therapeutics focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.